Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs

Executive Summary

All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years

You may also be interested in...



NME Safety Reviews Expected For Three More Drugs, With FDA Pilot Program Expansion

Agency's decision means that analysis of Doribax, Isentress and Bystolic will be forthcoming.

FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact

FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain

Pilot Program Will Review First-Year Safety Data for Several NMEs

FDA outlines organizational steps and safety monitoring initiatives in response to IoM report on improving drug safety.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel